147 related articles for article (PubMed ID: 8602615)
1. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.
Harlozińska A; Bar JK; Sedlaczek P; Gerber J
Am J Clin Pathol; 1996 Mar; 105(3):334-40. PubMed ID: 8602615
[TBL] [Abstract][Full Text] [Related]
2. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
Harlozińska A; Bar J; Montenarh M
Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396
[TBL] [Abstract][Full Text] [Related]
4. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; Boonstra H; Sweep CG
Cancer; 2001 Jan; 91(2):371-7. PubMed ID: 11180084
[TBL] [Abstract][Full Text] [Related]
7. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
8. Relationship between p53 and c-erbB-2 overexpression in tissue sections and cyst fluid cells of patients with ovarian cancer.
Harłozińska A; Bar JK
Tumour Biol; 1994; 15(4):223-9. PubMed ID: 7939171
[TBL] [Abstract][Full Text] [Related]
9. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer.
Montenarh M; Harloziñska A; Bar JK; Kartarius S; Günther J; Sedlaczek P
Int J Oncol; 1998 Sep; 13(3):605-10. PubMed ID: 9683801
[TBL] [Abstract][Full Text] [Related]
10. The presence of p53 protein in relation to Ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa.
Slootweg PJ; Koole R; Hordijk GJ
Eur J Cancer B Oral Oncol; 1994; 30B(2):138-41. PubMed ID: 8032302
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
[TBL] [Abstract][Full Text] [Related]
12. p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma.
Pindzola JA; Kovatich AJ; Bibbo M
Acta Cytol; 2000; 44(1):31-6. PubMed ID: 10667156
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.
Gorczyca W; Markiewski M; Kram A; Tuziak T; Domagala W
Virchows Arch; 1995; 426(3):229-33. PubMed ID: 7773501
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
[TBL] [Abstract][Full Text] [Related]
15. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
16. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
17. Relations between immunologically different p53 forms, p21(WAF1) and PCNA expression in ovarian carcinomas.
Harlozinska A; Bar JK; Montenarh M; Kartarius S
Oncol Rep; 2002; 9(6):1173-9. PubMed ID: 12375014
[TBL] [Abstract][Full Text] [Related]
18. nm23 expression in tissue sections and tumor effusion cells of ovarian neoplasms.
Harłozińska A; Bar JK; Gerber J
Int J Cancer; 1996 Oct; 69(5):415-9. PubMed ID: 8900377
[TBL] [Abstract][Full Text] [Related]
19. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer.
Mizera-Nyczak E; Dyszkiewicz W; Heider KH; Zeromski J
Tumour Biol; 2001; 22(1):45-53. PubMed ID: 11054026
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas. Correlation with clinicopathology and sex steroid receptor status.
Koshiyama M; Konishi I; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Mori T
Virchows Arch; 1995; 425(6):603-9. PubMed ID: 7697217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]